Investor Relations

Corporate Profile

Headquartered in China and founded in 2014, Burning Rock, whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology.

Our business consists of (i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and (ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

We are China’s number one NGS-based cancer therapy selection company, as evidenced by the largest market share in China’s NGS-based cancer therapy selection market in terms of number of patients tested in 2019, according to China Insights Consultancy.

Latest Quarterly Earnings

Print Page
RSS Feeds
Email Alerts